Welcome to our dedicated page for Progyny SEC filings (Ticker: PGNY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Progyny, Inc. filings document public-company reporting for its Nasdaq-listed common stock and its women's health and family building benefits business. Recent Form 8-K reports furnish quarterly and annual financial results, guidance updates, Regulation FD materials, supplemental earnings presentations, and other material-event disclosures.
The company's proxy materials cover annual meeting governance, director and executive compensation, equity award information, and related shareholder voting matters. Other filings address executive employment and compensatory arrangements, as well as a derivative-action settlement notice tied to historical non-employee director compensation practices.
Progyny, Inc. (PGNY) reported that its chief financial officer, Mark S. Livingston, had common shares withheld in early September 2026 to cover tax obligations from vesting equity awards. On September 3, 2026, 1,532 shares were withheld at $26.29 per share, and on September 2, 2026, 224 shares were withheld at $25.66 per share. A footnote states these were shares withheld for payment of withholding taxes upon the vesting of restricted stock units granted to him, rather than open-market sales.
Progyny, Inc. (PGNY) reported an insider equity tax event involving executive Allison Swartz, EVP and General Counsel. On August 28, 2026, Swartz had 1,352 shares of common stock withheld at $25.86 per share to pay withholding taxes upon vesting of restricted stock units. After this non-open-market, tax-withholding disposition, Swartz directly holds 81,026 shares of Progyny common stock.
Progyny, a fertility and women’s health benefits company, reported second‑quarter 2026 revenue of $350,511 (in thousands), up from $332,874 (in thousands) a year earlier, with fertility benefits and integrated pharmacy services both contributing. Gross margin improved to 25.5% from 23.7%.
Operating expenses declined as a share of revenue to 14.1%, while stock‑based compensation fell to $20,478 (in thousands) from $32,383 (in thousands). Income from operations rose to $40,003 (in thousands), and net income increased to $28,052 (in thousands), or $0.34 diluted EPS. Adjusted EBITDA was $62,104 (in thousands), a 17.7% margin. As of June 30, 2026, Progyny reported $715,836 (in thousands) of total assets and stockholders’ equity of $453,257 (in thousands), and it actively returned capital, repurchasing 6,700,337 shares in the first half of 2026 at an average price of $22.08 per share.
Progyny, Inc. reported second quarter 2026 revenue of $350.5 million, up from $332.9 million a year earlier, driven by more clients and covered lives and with no contribution from a large former client. Gross profit rose to $89.3 million with a 25.5% margin.
Net income was $28.1 million, or $0.34 per diluted share, compared with $17.1 million, or $0.19, while Adjusted EBITDA increased to $62.1 million with a 17.7% margin. Operating cash flow was $50.4 million. The company ended June 30, 2026 with $236.9 million in cash, cash equivalents and marketable securities, $272.9 million of working capital, no debt and an undrawn $200 million revolver.
Progyny repurchased nearly 1.2 million shares for $31.5 million in the quarter and 2.0 million shares under its May 2026 authorization, leaving $142.5 million available. For full year 2026 it projects revenue of $1.360–$1.385 billion and net income of $104.8–$109.9 million.
FMR LLC and Abigail P. Johnson report beneficial ownership of common stock of Progyny, Inc. FMR LLC is shown with 7,004,279.53 shares beneficially owned, representing 8.9% of the common stock outstanding as of June 30, 2026. FMR LLC has sole voting power over 7,003,929 shares and sole dispositive power over 7,004,279.53 shares, with no shared voting or dispositive power.
Abigail P. Johnson is reported with sole dispositive power over 7,004,279.53 shares, also corresponding to 8.9% of the class, and no voting power. One or more other persons have the right to receive dividends or sale proceeds from these shares, but no such person holds more than five percent of Progyny’s outstanding common stock.
Progyny, Inc. Chief Operating Officer Melissa B. Cummings reported insider transactions in Common Stock. On July 14, 2026, she executed an open-market sale of 2,244 shares at $31.60 per share under a pre-arranged Rule 10b5-1 trading plan. On the same date, 1,193 shares were disposed of to cover withholding taxes upon the vesting of restricted stock units. The tax-related share disposition was not an open-market sale.
A PGNY stockholder filed a notice of intent to sell 2,244 shares of common stock through Fidelity Brokerage Services LLC on July 14, 2026 on NASDAQ, with an aggregate market value of $70,910.40. These shares arose from restricted stock vesting as compensation dated the same day. The filer also reports a prior sale of 9,578 shares of common stock on May 19, 2026, with an aggregate amount of $239,450.00.
Progyny, Inc. Chief Product Officer Geoffrey Clapp reported a routine share disposition related to taxes. On June 17, 2026, 819 shares of common stock were withheld at $26.60 per share to cover withholding taxes upon the vesting of restricted stock units. After this tax-withholding transaction, Clapp directly held 59,828 shares of Progyny common stock. This was not an open-market sale but an automatic share withholding to satisfy tax obligations tied to equity compensation.
Progyny, Inc. amended a Schedule 13G/A (Amendment No. 4) reporting beneficial ownership information for Kleiner Perkins entities. The cover identifies CUSIP 74340E103 and a reporting date of 03/31/2025. The filing notes zero voting and dispositive power and 0% percent of the class shown on the cover rows. The amendment is signed by Susan Biglieri on 06/05/2026 and includes an Agreement of Joint Filing as Exhibit A.
Progyny, Inc. chief financial officer Mark S. Livingston reported small routine transactions in the company’s common stock. On June 4, 2026, he sold a total of 2,517 shares in open-market trades at $25.50 per share pursuant to a pre-arranged Rule 10b5-1 trading plan. In addition, 1,421 shares were withheld on June 3 and June 4 to cover withholding taxes upon the vesting of restricted stock units. Following these transactions, Livingston directly holds 74,688 shares of Progyny common stock.